Genmab's Impressive Financial Performance in H1 2024
Genmab A/S, a leading biotechnology company, has reported a significant financial growth for the first half of 2024. The company saw its revenue jump by 36%, reaching over DKK 9.5 billion. This robust growth was accompanied by a 29% increase in operating profit, totaling DKK 2.4 billion. This financial success is bolstered by the strategic acquisition of ProfoundBio, which is expected to drive long-term growth.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
